Latest Articles
Endometrial mRNA therapy could treat infertility - MSN
Endometrial mRNA therapy could treat infertility MSN
Published: Jan. 21, 2026, 4:25 a.m.
Researchers find early success with mRNA therapy to treat infertility - wbaltv.com
Researchers find early success with mRNA therapy to treat infertility wbaltv.com
Published: Jan. 20, 2026, 10:34 p.m.
Hopkins researchers find early success with endometrial mRNA therapy to treat infertility - WBAL-TV
Hopkins researchers find early success with endometrial mRNA therapy to treat infertility WBAL-TV
Published: Jan. 20, 2026, 6:38 p.m.
Hopkins researchers find early success with endometrial mRNA therapy to treat infertility - wbaltv.com
Hopkins researchers find early success with endometrial mRNA therapy to treat infertility wbaltv.com
Published: Jan. 20, 2026, 6:38 p.m.
Endometrial mRNA therapy to treat infertility finds early success - Phys.org
Endometrial mRNA therapy to treat infertility finds early success Phys.org
Published: Jan. 19, 2026, 8:32 p.m.
Johns Hopkins Medicine Researchers Find Early Success Using Endometrial mRNA Therapy to Treat Infertility | Newswise - Newswise
Johns Hopkins Medicine Researchers Find Early Success Using Endometrial mRNA Therapy to Treat Infertility | Newswise Newswise
Published: Jan. 19, 2026, 2 p.m.
Immunotherapy for Advanced Endometrial Cancer - Banner Health
Immunotherapy for Advanced Endometrial Cancer Banner Health
Published: Jan. 8, 2026, 12:51 p.m.
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy - Targeted Oncology
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy Targeted Oncology
Published: Jan. 5, 2026, 1:07 p.m.
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer Nasdaq
Published: Dec. 22, 2025, 11:34 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - The AI Journal
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer The AI Journal
Published: Dec. 22, 2025, 7:31 a.m.
Link copied to clipboard!